On Thursday, October 10, 2024, the shares of pharmaceutical giant Lupin Limited witnessed a sharp fall of 5.54% and closed at ₹2,157.60. This decline comes despite an overall rise in the Sensex, indicating specific concerns impacting Lupin’s stock. This fall came after the United States Food and Drug Administration (USFDA) issued 5 observations following an …